Synthesis of new analogs of tetraiodothyroacetic acid (tetrac) as novel angiogenesis inhibitors for treatment of cancer
dc.contributor.author | Rajabi, Mehdi | |
dc.contributor.author | Mousa, Shaker A. | |
dc.contributor.buuauthor | Yalçın, Murat | |
dc.contributor.department | Uludağ Üniversitesi/Veteriner Fakültesi/Fizyoloji Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0002-5600-8162 | tr_TR |
dc.contributor.researcherid | AAG-6956-2021 | tr_TR |
dc.contributor.scopusid | 57192959734 | tr_TR |
dc.date.accessioned | 2024-03-25T12:53:17Z | |
dc.date.available | 2024-03-25T12:53:17Z | |
dc.date.issued | 2018-02-24 | |
dc.description.abstract | In the angiogenesis process, integrins, which are members of a family of cell surface transmembrane receptors, play a critical role particularly in blood vessel formation and the local release of vascular growth factors. Thyroid hormones such as L-thyroxine (T-4) and 3,5,30-triiodo-L-thyronine (T-3) promote angiogenesis and tumor cell proliferation via integrin alpha v beta 3 receptor. At or near an arginine-glycine-aspartate (RGD) recognition site on the binding pocket of integrin avb3, tetraiodothyroacetic acid (tetrac, a deaminated derivative of T-4) is a thyrointegrin receptor antagonist and blocks the actions of T-3 and T-4 as well as different growth factors-mediated angiogenesis. In this study, we synthesized novel tetrac analogs by modifying the phenolic moiety of tetrac and tested them for their anti-angiogenesis activity using a Matrigel plug model for angiogenesis in mice. Pharmacological activity results showed that tetrac can accommodate numerous modifications and maintain its anti-angiogenesis activity. | en_US |
dc.description.sponsorship | NanoPharmaceuticals LLC | en_US |
dc.description.sponsorship | Pharmaceutical Research Institute at the Albany College of Pharmacy and Health Sciences | en_US |
dc.identifier.citation | Rajabi, M. vd. (2018). ''Synthesis of new analogs of tetraiodothyroacetic acid (tetrac) as novel angiogenesis inhibitors for treatment of cancer''. Bioorganic and Medicinal Chemistry Letters, 28(7), 1223-1227. | en_US |
dc.identifier.doi | https://doi.org/10.1016/j.bmcl.2018.02.045 | |
dc.identifier.eissn | 1464-3405 | |
dc.identifier.endpage | 1227 | tr_TR |
dc.identifier.issn | 0960-894X | |
dc.identifier.issue | 7 | tr_TR |
dc.identifier.pubmed | 29519736 | tr_TR |
dc.identifier.scopus | 2-s2.0-85042873643 | tr_TR |
dc.identifier.startpage | 1223 | tr_TR |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0960894X18301501 | en_US |
dc.identifier.uri | https://hdl.handle.net/11452/40618 | en_US |
dc.identifier.volume | 28 | tr_TR |
dc.identifier.wos | 000428092400013 | tr_TR |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Pergamon-Elsevier Science | en_US |
dc.relation.collaboration | Sanayi | tr_TR |
dc.relation.journal | Bioorganic and Medicinal Chemistry Letters | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Pharmacology & pharmacy | en_US |
dc.subject | Chemistry | en_US |
dc.subject | Angiogenesis | en_US |
dc.subject | Thyroid hormones | en_US |
dc.subject | Tetraiodothyroacetic acid | en_US |
dc.subject | Tetrac | en_US |
dc.subject | Integrin | en_US |
dc.subject | L-thyeoxine | en_US |
dc.subject | Tumor | en_US |
dc.subject | Thalidomide | en_US |
dc.subject | Growth | en_US |
dc.subject | Metabolites | en_US |
dc.subject | Integrins | en_US |
dc.subject.emtree | Angiogenesis inhibitor | en_US |
dc.subject.emtree | Antineoplastic agent | en_US |
dc.subject.emtree | Tetraiodothyroacetic acid | en_US |
dc.subject.emtree | Tetraiodothyroacetic acid derivative | en_US |
dc.subject.emtree | Thalidomide | en_US |
dc.subject.emtree | Unclassified drug | en_US |
dc.subject.emtree | Angiogenesis inhibitor | en_US |
dc.subject.emtree | Antineoplastic agent | en_US |
dc.subject.emtree | Tetraiodothyroacetic acid | en_US |
dc.subject.emtree | Thyroxine | en_US |
dc.subject.emtree | Animal experiment | en_US |
dc.subject.emtree | Animal model | en_US |
dc.subject.emtree | Antiangiogenic activity | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Cancer chemotherapy | en_US |
dc.subject.emtree | Chemical modification | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Drug solubility | en_US |
dc.subject.emtree | Drug synthesis | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | In vivo study | en_US |
dc.subject.emtree | Liquid chromatography | en_US |
dc.subject.emtree | Mass spectrometry | en_US |
dc.subject.emtree | Mouse | en_US |
dc.subject.emtree | Mouse model | en_US |
dc.subject.emtree | Nonhuman | en_US |
dc.subject.emtree | Structure activity relation | en_US |
dc.subject.emtree | Analogs and derivatives | en_US |
dc.subject.emtree | Animal | en_US |
dc.subject.emtree | C57BL mouse | en_US |
dc.subject.emtree | Cell proliferation | en_US |
dc.subject.emtree | Chemical structure | en_US |
dc.subject.emtree | Chemistry | en_US |
dc.subject.emtree | Disease model | en_US |
dc.subject.emtree | Dose response | en_US |
dc.subject.emtree | Drug effect | en_US |
dc.subject.emtree | Drug screening | en_US |
dc.subject.emtree | Experimental neoplasm | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Neoplasm | en_US |
dc.subject.emtree | Neovascularization (pathology) | en_US |
dc.subject.emtree | Pathology | en_US |
dc.subject.emtree | Synthesis | en_US |
dc.subject.mesh | Angiogenesis inhibitors | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Antineoplastic agents | en_US |
dc.subject.mesh | Cell proliferation | en_US |
dc.subject.mesh | Disease models, animal | en_US |
dc.subject.mesh | Dose-response relationship, drug | en_US |
dc.subject.mesh | Drug screening assays, antitumor | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Mice | en_US |
dc.subject.mesh | Mice, inbred C57BL | en_US |
dc.subject.mesh | Molecular structure | en_US |
dc.subject.mesh | Neoplasms | en_US |
dc.subject.mesh | Neoplasms, experimental | en_US |
dc.subject.mesh | Neovascularization, pathologic | en_US |
dc.subject.mesh | Structure-activity relationship | en_US |
dc.subject.mesh | Thyroxine | en_US |
dc.subject.scopus | Integrin; Thyroid Hormones; Nano-Diamino-Tetrac | en_US |
dc.subject.wos | Chemistry, medicinal | en_US |
dc.subject.wos | Chemistry, organic | en_US |
dc.title | Synthesis of new analogs of tetraiodothyroacetic acid (tetrac) as novel angiogenesis inhibitors for treatment of cancer | en_US |
dc.type | Article | en_US |
dc.wos.quartile | Q3 (Chemistry, medicinal) | en_US |
dc.wos.quartile | Q2 (Chemistry, organic) | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: